|Bid||206.00 x 900|
|Ask||208.64 x 800|
|Day's Range||197.99 - 217.17|
|52 Week Range||50.00 - 217.17|
|Beta (5Y Monthly)||1.61|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 23, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|Ex-Dividend Date||Sep 26, 2012|
|1y Target Est||192.50|
Heska jumped almost 4.2% to close at $196.53 on Feb. 23 after the advanced veterinary diagnostic and specialty healthcare products provider swung to a surprise profit in the fourth quarter. Total revenue jumped 90.5% to $64.3 million year-over-year and topped analysts’ estimates of $53.09 million. Sales during the reported quarter were driven by a rise in active subscriptions and North America point of care (POC) lab consumables. Heska (HSKA) reported 4Q adjusted earnings of $0.72 per share, compared to earnings of $0.10 per share during the same quarter last year. Analysts had expected the company to report a loss of $0.22 per share. North America segment revenue came in at $40 million in 4Q, up 29.3% year-over-year. Adjusted EBITDA margin increased by 220 basis points to 13.4%. (See Heska stock analysis on TipRanks) Heska CEO Kevin Wilson commented, “We saw healthy growth driven by healthy end markets that continue to need more of what Heska has unique capability to offer, all of which forms a great foundation to continue to upscale revenue and profitability in this second half of our Act Two plan.” For 2021, the company projects total revenue in the range of $225 million to $235 million. The adjusted EBITDA margin is anticipated to be 8%. Additionally, the number of active subscriptions is expected to reach 3,715. Following the 4Q results, Piper Sandler analyst Steven Mah increased the stock’s price target to $220 (11.9% upside potential) from $157 and maintained a Buy rating. In a note to investors, the analyst said, “Heska’s business model has shown strong resiliency despite COVID-19 headwinds.” Mah believes “the company is positioned for long-term sustainable growth with upcoming product launches, entry into cytology increasing international traction, plus ongoing strength in pet ownership trends extending into 2021.” Heska shares have exploded almost 95% over the past year, while the stock still scores a Strong Buy consensus rating based on 3 unanimous Buys. That’s alongside an average analyst price target of $176, which implies downside potential of more than 10% to current levels over the next 12 months. Additionally, Heska scores a “Perfect 10” from TipRanks’ Smart Score rating system, indicating that the stock has strong potential to outperform market expectations. Related News: Freshpet Dips 3% Pre-Market On Surprise Quarterly Loss; Street Is Bullish EverQuote Jumps 8% Pre-Market On Better-Than-Feared Quarterly Loss CVR Energy Tanks 9% On Quarterly Loss; Street Says Hold More recent articles from Smarter Analyst: Macy’s Beats 4Q Sales Estimates, Sees Recovery In 2021; Shares Drop 2.6% Crocs Posts Record Sales Quarter; Shares Sink 5% Carnival Plans To Raise $1B Via Share Sale; Stock Falls 4% Installed Building Initiates Quarterly Dividend; Street Is Bullish
With us this morning, we have Kevin Wilson, Heska's Chief Executive Officer and President; and Catherine Grassman, Heska's Chief Financial Officer. Mr. Wilson and Ms. Grassman will provide details surrounding the results reported as well as the company's 2021 outlook, and then we will open the call to questions.
Shares of Heska (NASDAQ:HSKA) were unchanged after the company reported Q4 results. Quarterly Results Earnings per share were up 928.57% over the past year to $0.72, which beat the estimate of ($0.22). Revenue of $64,322,000 up by 90.49% year over year, which beat the estimate of $53,090,000. Looking Ahead Heska hasn't issued any earnings guidance for the time being. The upcoming fiscal year's revenue expected to be between $225,000,000 and $235,000,000. Details Of The Call Date: Feb 23, 2021 View more earnings on HSKA Time: 11:00 AM ET Webcast URL: http://public.viavid.com/player/index.php?id=143209 Recent Stock Performance Company's 52-week high was at $206.85 Company's 52-week low was at $50.00 Price action over last quarter: Up 50.55% Company Profile Heska Corp is engaged in developing, manufacturing, marketing, selling & supporting veterinary products. The company's segments are Core Companion Animal Health & Other Vaccines, Pharmaceuticals and Products. The CCA segment includes, primarily for canine & feline use, a point of care laboratory instruments & supplies, digital imaging products, software & services, local & cloud-based data services, allergy testing & immunotherapy, & single-use offerings such as point of care diagnostic tests and heartworm preventive products. The OVP segment includes private label vaccine and pharmaceutical production, primarily for cattle but also for other species including equine, porcine, avian, feline & canine. See more from BenzingaClick here for options trades from BenzingaEarnings Scheduled For February 23, 2021© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.